MX2023008726A - Uso de esteroides neuroactivos para el tratamiento de la disfuncion sexual. - Google Patents

Uso de esteroides neuroactivos para el tratamiento de la disfuncion sexual.

Info

Publication number
MX2023008726A
MX2023008726A MX2023008726A MX2023008726A MX2023008726A MX 2023008726 A MX2023008726 A MX 2023008726A MX 2023008726 A MX2023008726 A MX 2023008726A MX 2023008726 A MX2023008726 A MX 2023008726A MX 2023008726 A MX2023008726 A MX 2023008726A
Authority
MX
Mexico
Prior art keywords
treatment
sexual dysfunction
neuroactive steroids
patient
neuroactive
Prior art date
Application number
MX2023008726A
Other languages
English (en)
Spanish (es)
Inventor
Handan Gunduz-Bruce
Vijayveer Bonthapally
Ellison Suthoff
Ryan Arnold
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2023008726A publication Critical patent/MX2023008726A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MX2023008726A 2021-01-28 2022-01-27 Uso de esteroides neuroactivos para el tratamiento de la disfuncion sexual. MX2023008726A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142840P 2021-01-28 2021-01-28
US202163142833P 2021-01-28 2021-01-28
PCT/US2022/014075 WO2022165017A1 (en) 2021-01-28 2022-01-27 Use of neuroactive steroids for treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
MX2023008726A true MX2023008726A (es) 2023-12-14

Family

ID=80787167

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008726A MX2023008726A (es) 2021-01-28 2022-01-27 Uso de esteroides neuroactivos para el tratamiento de la disfuncion sexual.

Country Status (9)

Country Link
US (1) US20240122945A1 (cg-RX-API-DMAC7.html)
EP (1) EP4284382A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024507638A (cg-RX-API-DMAC7.html)
KR (1) KR20230136599A (cg-RX-API-DMAC7.html)
AU (1) AU2022214187A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206537A1 (cg-RX-API-DMAC7.html)
IL (1) IL304080A (cg-RX-API-DMAC7.html)
MX (1) MX2023008726A (cg-RX-API-DMAC7.html)
WO (1) WO2022165017A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
IL309922A (en) * 2021-07-28 2024-03-01 Sage Therapeutics Inc Crystalline forms of a neuroactive steroid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080080094A (ko) * 2005-10-14 2008-09-02 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
EP3068226A4 (en) * 2013-11-11 2017-05-17 Euthymics Bioscience, Inc. Novel methods
SI3705488T1 (sl) * 2014-05-29 2022-10-28 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporaba le-teh
PH12018501923B1 (en) * 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
MX2021010744A (es) * 2019-03-04 2022-01-18 Praxis Prec Medicines Inc Metodos para el tratamiento de la perimenopausia y la menopausia.
US20230210870A1 (en) * 2020-06-08 2023-07-06 Eliem Therapeutics, Inc. Methods of treating female health conditions related to sex hormones

Also Published As

Publication number Publication date
JP2026120717A (ja) 2026-07-22
EP4284382A1 (en) 2023-12-06
CA3206537A1 (en) 2022-08-04
US20240122945A1 (en) 2024-04-18
JP2024507638A (ja) 2024-02-21
KR20230136599A (ko) 2023-09-26
WO2022165017A1 (en) 2022-08-04
AU2022214187A9 (en) 2024-05-23
IL304080A (en) 2023-08-01
AU2022214187A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
MX2020008777A (es) Inmunoterapias relacionadas con el microbioma.
EP4667055A3 (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2009011540A (es) Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo.
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2025008078A (es) Semaglutida para el tratamiento de la esteatohepatitis no alcoholica
PH12022551021A1 (en) Sequential anti-cd19 therapy
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
ZA202304965B (en) Combination therapy for treating cancer
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2019009586A (es) Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.
MX2025000673A (es) Metodos de administracion de nalbufina
ZA202104786B (en) Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022004785A (es) Metodos y composiciones para el tratamiento del sindrome de rett.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2021000908A (es) Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
PH12022551512A1 (en) Synthetic processes and intermediates
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
WO2020025657A9 (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa
EP4467131A3 (en) Microbiota restoration therapy (mrt) compositions and methods of manufacture
MX2020007404A (es) Metodos y terapia de combincion para tratar cancer.
MX2019015448A (es) Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar.